He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...

Visit a quote page and your recently viewed tickers will be displayed here. Severin Schwan currently works at Roche Group, as Chief Executive Officer from 2008, Roche Holding AG, as Chairman from 2023 ...

Detailed price information for Roche Holding Div RTS (RHHVF) from The Globe and Mail including charting and trades.

Roche Holding AG and Zealand Pharma A/S shares plummeted Friday after their experimental obesity shot failed to meet industry ...

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

Detailed price information for Roche Holding Div RTS (RHHVF) from The Globe and Mail including charting and trades.

The average one-year price target for Roche Holding AG - Depositary Receipt (OTCPK:RHHBY) has been revised to $76.66 / share. This is a decrease of 10.04% from the prior estimate of $85.21 dated ...

Earnings call Roche reported 7% group sales growth YTD (constant exchange rates), with Pharma up 9% and Diagnostics up 1% (7% ex-China). Management raised core EPS guidance to high single-digit to low ...